1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384 (9945): 766–781.
2. WHO. Obesity and overweight. 2016. http://who.int/mediacentre/factsheets/fs311/en/.
3. De Onis M., Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010; 92 (5): 1257–1264.
4. OECD. Obesity update. 2017. http://www.oecd.org/health/health-systems/Obesity-Update-2017.pdf.
5. OECD. Overweight and obesity among children. Health at a Glance 2017: OECD Indicators, OECD Publishing, Paris. https://doi.org/10.1787/health_glance-2017-22-en.
6. Hainer V, et al. Základy klinické obezitologie. 2. prepracované a doplnené vyd. Praha: Grada Publishing, 2011.
7. Toschke AM, Vignerova J, Lhotska L, et al. Overweight and obesity in 6- to 14-year-old Czech children in 1991: protective effect of breast--feeding. J Pediatr 2002; 141 (6): 764–769.
8. Czippelová B, Turianiková Z, Krohová J, et al. Arterial stiffness in obese adolescents – a relation to vascular resistance and sympathetic nervous system activity. Acta Physiol 2017; 221: Suppl: S713.
9. Durdík P, Sujanska A, Suroviakova S, et al. Sleep architecture in children with common phenotype of obstructive sleep apnea. J Clin Sleep Med 2018; 14 (1): 9–14.
10. Šujanská A, Ďurdík P, Suroviaková S, et al. Chrápanie u detí predškolského a školského veku. Lek Obz 2016; 65 (11): 412–417.
11. Suroviaková S, Šujanská A, Ďurdík P, et al. Centrálne spánkove apnoe u detí. Lek Obz 2016; 65 (11): 433–437.
12. Pražienková V, Holubová M, Pelantová H, et al. Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity. PLoS One 2017; 12 (8): e0183449.
13. Javorka K, et al. Lekárska fyziológia. Tretie, prepracované a doplnené vydanie. Martin: Osveta, 2009.
14. Lane N. Oxygen: The Molecule that Made the World. Oxford: Oxford University Press, 2002.
15. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001; 81 (2): 629–683.
16. Kiss A, Mikkelsen JD. Oxytocin – anatomy and functional assignments: a minireview. Endocr Regul 2005; 39 (3): 97–105.
17. NCBI. LNPEP leucyl and cystinyl aminopeptidase [Homo sapiens (human)]. 2019. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=4012.
18. Fjellestad-Paulsen A, Lundin S. Metabolism of vasopressin, oxytocin and their analogues [Mpa1, D-Arg8]-vasopressin (dDAVP) and [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (anatocin) in human kidney and liver homogenates. Regul Pept 1996; 67 (1): 27–32.
19. Smith R. Parturition. N Engl J Med 2007; 356 (3): 271–283.
20. Yang HP, Wang L, Han L, et al. Nonsocial functions of hypothalamic oxytocin. ISRN Neuroscience 2013. doi: 10.1155/2013/179272.
21. Ho JM, Blevins JE. Coming full circle: Contributions of central and peripheral oxytocin actions to energy balance. Endocrinology 2013; 154 (2): 589–596.
22. Deblon N, Veyrat-Durebes C, Bourgoin L, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induces obese rats. PLoS One 2011; 6 (9): e25565.
23. Morton GJ, Thatcher BS, Reidelberger RD, et al. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 2012; 302: E124–E144.
24. Blevins JE, Graham JL, Morton GJ, et al. Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 2015; 308: R431–R438.
25. Klement J, Ott V, Rapp K, et al. Oxytocin improves β-cell responsivity and glucose tolerance in healthy men. Diabetes 2017; 66 (2): 264–271.
26. Elabd SK, Sabry I, Mohasseb M, et al. Oxytocin as a novel therapeutic option for type I diabetes and diabetic osteopathy. Endocr Regul 2014; 48 (2): 87–102.
27. Zhang H, Wu C, Chen Q, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One 2013; 8: e61477.
28. Maejima Y, Iwasaki Y, Yamahara Y, et al. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Albany NY) 2011; 3 (12): 1169–1177.
29. Zhang G, Bai H, Zhang H, et al. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron 2011; 69 (3): 523–535.
30. Watanabe S, Wei FY, Matsunaga T, et al. Oxytocin protects against stress-induced cell death in murine pancreatic β-cells. Sci Rep 2016; 6: 25185.
31. Altirriba J, Poher AL, Caillon A, et al. Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology 2014; 155 (11): 4189–4201.
32. Perello M, Raingo J. Leptin activates oxytocin neurons of the hypothalamic paraventricular nucleus in both control and diet-induced obese rodents. PLoS One 2013; 8 (3): e59625.
33. Altirriba J, Poher AL, Rohner-Jeanrenaud F. Chronic oxytocin administration as a treatment against impaired leptin signaling or leptin resistance in obesity. Front Endocrinol (Lausanne) 2015; 6: 119.
34. Plante E, Menaouar A, Danalache BA, et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology 2015; 156 (4): 1416–1428.
35. Husarova VM, Lakatosova S, Pivovarciova A, et al. Plasma oxytocin in children with autism and its correlations with behavioral parameters in children and parents. Psychiatry Investig 2016;13 (2): 174–183.
36. Ozsoy S, Esel E, Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009; 169 (3): 249–252.
37. Kaye WH. Neuropeptide abnormalities in anorexia nervosa. Psychiatry Res 1996; 62 (1): 65–74.
38. Lawson EA, Donoho DA, Blum JI, et al. Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. J Clin Psychiatry 2011; 72 (11): 1546–1551.
39. Afinogenova Y, Schmelkin C, Plessow F, et al. Low fasting oxytocin levels are associated with psychopathology in anorexia nervosa in partial recovery. J Clin Psychiatry 2016; 77 (11): e1483–e1490.
40. Hoffman ER, Brownley KA, Hamer RM, et al. Plasma, salivary, and urinary oxytocin in anorexia nervosa: a pilot study. Eat Behav 2012; 13 (3): 256–259.
41. Monteleone AM, Scognamiglio P, Volpe U, et al. Investigation of oxytocin secretion in anorexia nervosa and bulimia nervosa: Relationships to temperament personality dimensions. Eur Eat Disord Rev 2016; 24 (1): 52–56.
42. Qian W, Zhu T, Tang B, et al. Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J Clin Endocrinol Metab 2014; 99 (12): 4683–4689.
43. Gajdosechova L, Krskova K, Segarra AB, et al. Hypooxytocinaemia in obese zucker rats relates to oxytocin degradation in liver and adipose tissue. J Endocrinol 2014; 220 (3): 333–343.
44. Yuan G, Qian W, Pan R, et al. Reduced circulating oxytocin and high-molecular-weight adiponectin are risk factors for metabolic syndrome. Endocr J 2016; 63 (7): 655–662.
45. Binay Ç, Paketçi C, Güzel S, et al. Serum irisin and oxytocin levels as predictors of metabolic parameters in obese children. J Clin Res Pediatr Endocrinol 2017; 9 (2): 124–131.
46. Eisenberg Y, Dugas LR, Akbar A, et al. Oxytocin is lower in African American men with diabetes and associates with psycho-social and metabolic health factors. PLoS One 2018; 4 (13): e0190301.
47. Kujath AS, Quinn L, Elliott ME, et al. Oxytocin levels are lower in premenopausal women with type 1 diabetes mellitus compared with matched controls. Diabetes Metab Res Rev 2015; 31 (1): 102–112.
48. Schroeder M, Zahoory-Sharon O, Shbiro L, et al. Development of obesity in the Otsuka Long-Evans Tokushima Fatty rat. Am J Physiol Regul Integr Comp Physiol 2009; 297 (6): R1749–R1760.
49. Szulc P, Amri EZ, Varennes A, et al. High serum oxytocin is associated with metabolic syndrome in older men. Diabetes Res Clin Pract 2016; 122: 17–27.
50. Schorr M, Marengi DA, Pulumo RL, et al. Oxytocin and its relationship to body composition, bone mineral density, and hip geometry across the weight spectrum. J Clin Endocrinol Metab 2017; 102 (8): 2814–2824.
51. Al-Nouaaimi MM, Kasabri V, Akour A, et al. Evaluation of the correlation of oxytocin plasma levels and metabolic syndrome biomarkers (leptin, adiponectin and resistin) in newly diagnosed type 2 diabetes patients in Jordan: A cross sectional study. Jordan J Pharmaceutical Sciences 2016; 9 (2).
52. Al-Rawashdeh A, Kasabri V, Bulatova N, et al. The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan. Diabetes Metab Syndr 2016; 11 (1): 59–67.
53. Lawson EA, Ackerman KE, Slattery M, et al. Oxytocin secretion is related to measures of energy homeostasis in young amenorrheic athletes. J Clin Endocrinol Metab 2014; 99 (5): E881–E885.
54. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995; 80 (2): 573–579.
55. Bittel DC, Kibiryeva N, Dasouki M, et al. A 9-year-old male with a duplication of chromosome 3p25.3p26.2: Clinical report and gene expression analysis. Am J Med Genet A 2006; 140 (6): 573–579.
56. Johnson L, Manardo, AM, Miller JL, et al. Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings. Am J Med Genet A 2016; 170: 594–601.
57. Burnett LC, Leduc CA, Sulsona CR, et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J Clin Invest 2017; 127: 293–305.
58. Kuppens RJ, Donze SH, Hokkens-Koelega ACS. Promising effects of oxytocin on social and food-related behavior in your children with Prader-Willi syndrome: a randomised, double-blind, controlled crossover trial. Clin Endocrinol 2016; 85: 979–987.
59. Tauber M, Boulanouar K, Diene G, et al. The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome. Pediatrics 2017; 139: e20162976.
60. Akour A, Kasabri V, Bulatova N, et al. Association of oxytocin with glucose intolerance and inflammation biomarkers in metabolic syndrome patients with and without prediabetes. Rev Diabet Stud 2018; 14 (4): 364–371.
61. Hosny S, Bekhet M, Bahaaeldin A, et al. Serum oxytocin in elderly patiens with metabolic syndrome. Endocrine Abstracts 2018; 56: P564.
62. Blevins JE, Baskin DG. Translational and therapeutic potential of oxytocin as an anti-obesity strategy: insights from rodents, nonhuman primates and humans. Physiol Behav 2015; 152: 438–449.
63. Lawson EA, Marengi DA, DeSanti RL, et al. Oxytocin reduces caloric intake in men. Obesity 2015; 23 (5): 950–956.
64. Lee MR, Scheidweiler KB, Diao XX, et al. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin aasay. Mol Psychiatry 2018; 23 (1): 115–122.
65. Zhang G, Cai D. Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab 201; 301 (5): E1004–E1012.
66. Macdonald E, Dadds MR, Brennan JL, et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011; 36 (8): 1114–1126.
67. Anagnostou E, Soorya L, Bian J, et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res 2014; 1580: 188–198.
68. Miller JL, Tamura R, Butler MG, et al. Oxytocin treatment in children with Prader-Willi syndrome: a double-blind, placebo-controlled, crossover study. Am J Med Genet A 2017; 173: 1243–1250.
69. Kim YR, Eom JS, Yang JW, et al. The impact of oxytocin on food intake and emotion recognition in patients with eating disorders: A double blind single dose within-subject cross-over design. PLoS One 2015; 10 (9): e0137514.
70. Thienel M, Fritsche A, Heinrichs M, et al. Oxytocin‘s inhibitory effect on food intake is stronger in obese than normal-weight men. Int J Obes (Lond) 2016; 40 (11): 1707–1714.
71. Ott V, Finlayson G, Lehnert H, et al. Oxytocin reduces reward-driven food intake in humans. Diabetes 2013; 62 (10): 3418–3425.
72. Striepens N, Schröter F, Stoffel-Wagner B, et al. Oxytocin enhances cognitive control of food craving in women. Hum Brain Mapp 2016; 37 (12): 4276–4285.
73. Olszewski PK, Klockars A, Levine AS. Oxytocin and potential benefits for obesity treatment. Curr Opin Endocrinol Diabetes Obes 2017; 24 (5): 320–325.
74. Takayanagi Y, Kasahara Y, Onaka T, et al. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport 2008; 19 (9): 951–955.